Paper38947237
The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.
Arici M and 9 others. Front Med (Lausanne), 2024. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials. Papers, record 38947237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38947237
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References111
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23067652 | KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. | Am J Kidney Dis | 2012 | https://conductscience.org/library/papers/23067652 | PubMed |
| 2 | 16445274 | Hyperkalemia. | Am Fam Physician | 2006 | https://conductscience.org/library/papers/16445274 | PubMed |
| 3 | 33720773 | Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. | Circulation | 2021 | https://conductscience.org/library/papers/33720773 | PubMed |
| 4 | 35784710 | Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35784710 | PubMed |
| 5 | 34811750 | Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. | Br J Pharmacol | 2022 | https://conductscience.org/library/papers/34811750 | PubMed |
| 6 | 26325557 | Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. | JAMA | 2015 | https://conductscience.org/library/papers/26325557 | PubMed |
| 7 | 35061867 | Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. | Diabetes Care | 2022 | https://conductscience.org/library/papers/35061867 | PubMed |
| 8 | 20650892 | A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. | J Biol Chem | 2010 | https://conductscience.org/library/papers/20650892 | PubMed |
| 9 | 29276100 | Revisiting RAAS blockade in CKD with newer potassium-binding drugs. | Kidney Int | 2018 | https://conductscience.org/library/papers/29276100 | PubMed |
| 10 | 34514191 | Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease. | Kidney Int Rep | 2021 | https://conductscience.org/library/papers/34514191 | PubMed |
| 11 | 36742404 | Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/36742404 | PubMed |
| 12 | 33688855 | Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. | EClinicalMedicine | 2021 | https://conductscience.org/library/papers/33688855 | PubMed |
| 13 | 35023547 | Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. | Eur Heart J | 2022 | https://conductscience.org/library/papers/35023547 | PubMed |
| 14 | 29548765 | The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. | Kidney Int | 2018 | https://conductscience.org/library/papers/29548765 | PubMed |
| 15 | 29554312 | Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. | Eur Heart J | 2018 | https://conductscience.org/library/papers/29554312 | PubMed |
| 16 | 32970396 | Dapagliflozin in Patients with Chronic Kidney Disease. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32970396 | PubMed |
| 17 | 36335326 | Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. | Cardiovasc Diabetol | 2022 | https://conductscience.org/library/papers/36335326 | PubMed |
| 18 | 36303247 | Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. | Diabetol Metab Syndr | 2022 | https://conductscience.org/library/papers/36303247 | PubMed |
| 19 | 27431783 | Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment. | Clin Pharmacol Drug Dev | 2016 | https://conductscience.org/library/papers/27431783 | PubMed |
| 20 | 32802705 | Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. | Diabetol Int | 2020 | https://conductscience.org/library/papers/32802705 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42943236 | Safety and Efficacy of Finerenone in Diabetic Kidney Disease: A Single-Center Retrospective Real-World Comparative Study of Dosing and Clinical Decision-Making in Taiwan. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943236 | PubMed |
| 42193565 | Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption. | Behav Sci (Basel) | 2026 | https://conductscience.org/library/papers/42193565 | PubMed |
| 42192808 | Effects of a Single Sub-Anesthetic Dose of Ketamine in Tobacco Use Disorder: An Active-Placebo, Randomized Crossover Study. | Brain Sci | 2026 | https://conductscience.org/library/papers/42192808 | PubMed |
| 42171960 | Finerenone in Cardiorenal Disease: A Narrative Review of Molecular Mechanisms, Clinical Evidence, and Emerging Therapeutic Roles. | Cardiovasc Drugs Ther | 2026 | https://conductscience.org/library/papers/42171960 | PubMed |
| 41877062 | A systematic review and meta-analysis of mesenchymal stem cell therapy in diabetic nephropathy and lupus nephritis or proteinuric nephropathy. | BMC Nephrol | 2026 | https://conductscience.org/library/papers/41877062 | PubMed |
| 41824283 | Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets. | Curr Heart Fail Rep | 2026 | https://conductscience.org/library/papers/41824283 | PubMed |
| 41790294 | Comparative efficacy of mineralocorticoid receptor antagonists in prevention of adverse cardiovascular events: a network meta-analysis. | Heart Fail Rev | 2026 | https://conductscience.org/library/papers/41790294 | PubMed |
| 41765963 | Dissecting the role of mineralocorticoid receptors in binge-like alcohol drinking in mice: Finerenone as a potential pharmacotherapy. | Psychopharmacology (Berl) | 2026 | https://conductscience.org/library/papers/41765963 | PubMed |
| 41369803 | Chronic kidney disease following left ventricular assist device implantation: contemporary insights and future perspectives. | Heart Fail Rev | 2025 | https://conductscience.org/library/papers/41369803 | PubMed |
| 41301427 | Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines. | Biomolecules | 2025 | https://conductscience.org/library/papers/41301427 | PubMed |
| 40534883 | Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/40534883 | PubMed |
| 40021271 | Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY. | JACC Adv | 2025 | https://conductscience.org/library/papers/40021271 | PubMed |
| 39911073 | Cardiovascular Efficacy and Safety of Finerenone: A Meta-Analysis of Randomized Controlled Trials. | Clin Cardiol | 2025 | https://conductscience.org/library/papers/39911073 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38947237
GET https://conductscience.org/api/papers/v1/38947237/references?page=2